CoALL 2020 Registry

Author:  J. Dobke, Last modification: 2022/03/30

CoALL 2020 Registry

CoALL 2020 Registry for the diagnostic, treatment and follow-up of acute lymphoblastic leukemia, T- and B-precursor Non-Hodgkin lymphoma in children and adolescents


Acute lyphoblastic leukemia, T- and B-precursor Non-Hodgkin lymphomas



Problem / Objectives

The register collects person- and disease-specific data from children and adolescents who are treated in study centers of the former CoALL 08-09 study because of a newly diagnosed ALL / T-NHL or B-precursor NHL. Disease-related data on the biology and the course of the disease are collected.


  • Recording of all ALL as well as T- and B-precursor NHL diseases and their treatment in children and adolescents in the participating centers.
  • Recording of the morphological, cytogenetic, molecular genetic as well as immunophenotypic characteristics of ALL and T-/B-precursor NHL in children at the initial diagnosis and in the course.
  • Recording of the treatment response by minimal residual disease (MRD) during the course of therapy.
  • Recording the frequency of (molecular) relapse.
  • Determination of the overall survival and event-free survival.
  • Analysis of the influence of MRD-based risk classification and therapeu-tical decisions on overall survival and event-free survival in a historical comparison
Therapy / Study arms

The registry does not provide any specific treatment recommendations. Patients should be treated according to an established standard therapy currently applicable in Germany.
The study center also advises on individual therapy strategies in individual cases.

Inclusion Criteria
  • Primary acute lymphoblastic leukemia (ALL) or
  • ALL as a second malignancy or
  • Acute biphenotypical leukemia (after consultation and approval by the Study coordination centre) or
  • Acute undifferentiated leukemia (after consultation and approval by the Study coordination centre) or
  • Non-Hodgkin Lymphomas: T-NHL or B-precursor-NHL, if ther is no par-ticipation in the LBL 2018 study or
  • „Special“ cases of ALL-associated diseases (after consultation and ap-proval by the Study coordination centre) or
  • ALL relapse without participation in one of the IntReALL studies
  • Age at diagnosis < 18 or >= 18 (after consultation and approval by the Study coordination centre
  • Admission to an accredited paediatric oncology centre in accordance with the GBA decision "Paediatric Oncology"
  • Consent of the patient and legal representative
Exclusion Criteria
  • Missing consent of the patient and/or the legal representative
  • Patient with primary ALL with Philadelphia-Chromosome (BCR/ABL)
Recruitment unlimited
Status Start 01.01.2020; End 31.12.2030
Principal Investigator PD Dr. med. G. Escherich


PD Dr. med. Gabriele Escherich Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik f. Päd. Hämatologie u. Onkologie Martinistraße 52 20246 Hamburg Telefon +49 (40) 42803 3796 / 74 10- 5 2580 Fax +49 (40) 42803 3608


Kseniya Bakharevich Universitätsklinikum Hamburg-Eppendorf Klinik für Pädiatrische Hämatologie und Onkologie Martinistr. 52 20246 Hamburg Telefon +49 (0)40 7410 52580 Fax +49 (0)40 7410 58101

Participants 6 centres in Germany: Evangelisches Klinikum Bethel Bielefeld, Universi-tätsklinikum Bonn, Klinikum Bremen-Mitte, Universitätsklinikum Hamburg Eppendorf, Helios Klinikum Krefeld, Universitätsmedizin Mainz